

Salah-Dine Chibout



Member of the IHI JU Governing Board

Global Head of External Partnerships & Head of Oncology Therapeutic Area in Preclinical Safety, Novartis Institutes for BioMedical research (NIBR)

Chair of Research & Innovation Strategy Group (RIS) at the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Salah-Dine Chibout is Global Head of External Partnerships and Head of Oncology Therapeutic Area in Preclinical Safety for NIBR. In this role since 2019, he is responsible for the Oncology portfolio's safety strategy from target identification to market access. Salah-Dine is responsible for the outsourcing of preclinical safety activities.

Salah-Dine has more than 28 years of experience in drug development. He joined the Toxicology Department at Sandoz in 1990 and since then he has had held roles of increasing responsibilities at Sandoz and Novartis. He created the Discovery and Investigative Safety group, being responsible for investigating all drugs' side effects from discovery to market. From 2008 to 2010, he was Deputy Head of Translational Science in Europe. From 2010 to 2019, Salah-Dine was leading the Therapeutic Areas in Preclinical Safety. In this role, he was responsible for defining all regulatory required toxicity studies, generating the relevant regulatory documents and ensuring efficient interactions with health authorities. In addition, Salah-Dine is leading the External Partnerships department, being responsible for the outsourcing of toxicology activities and interactions with academics for preclinical safety.

Salah-Dine is responsible for the IMI/IHI public-private partnerships at Novartis. He represents Novartis at the EFPIA Science and Innovation Board and is the Chair of the Research & Innovation Strategy Group (RIS).

Salah-Dine holds a PhD in Molecular Immunology from the Biozentrum in Basel, Switzerland.